UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
SEC FILE NUMBER
  0-28666
 
CUSIP NUMBER
                                                                                                                                                                      024600
 
(Check One):    ☐ Form 10-K     ☐ Form 20-F     ☐ Form 11-K     ☒ Form 10-Q     ☐ Form 10-D     ☐ Form N-SAR
 
☐ Form N-CSR
 
For period ended June 30, 2021
 
☐  Transition Report on Form 10-K
 
☐  Transition Report on Form 20-F
 
☐  Transition Report on Form 11-K
 
☐  Transition Report on Form 10-Q
 
☐  Transition Report on Form N-SAR
 
For the Transition Period Ended:
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: Not Applicable
 
PART I - REGISTRANT INFORMATION
 
American Bio Medica Corporation
Full name of registrant
 
Not Applicable
Former Name if Applicable
 
122 Smith Road
Address of Pincipal Eecutive Ofice (Sreet and Number)
 
Kinderhook, New York 12106
City, Sate and Zip Code
 
 
 
 
PART II - RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
 ☒
(b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date, or the subject quarterly report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
 
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
 
PART III - NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed.)
 
The registrant was unable to timely file its requisite quarterly report on Form 10-Q for period ended June 30, 2021 by the prescribed due date of August 16, 2021. The Registrant needs additional time to process its Form 10-Q under the new inline XBRL (iXBRL) reporting requirements that became effective for the registrant on June 15, 2021.
 
In accordance with Rule 12b-25 promulgated under the Securities and Exchance Act of 1934, as amended, the Registrant intends to file its Form 10-Q on or prior to August 23, 2021.
 
PART IV - OTHER INFORMATION
 
(1)            
Name and telephone number of person to contact in regard to this notification:
 
 Melissa A. Waterhouse
 (518)
 758-8158
 (Name)
 (Area Code)
 (Telephone Number)
 
(2) 
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, please identity report(s).

☒ Yes    No ☐
 
(3) 
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes   No ☒
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
AMERICAN BIO MEDICA CORPORATION
(Name of Registrant as Specified in Charter)
 
Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

 
 
 
 
 
Date: August 16, 2021
By:  
/s/ Melissa A. Waterhouse  
 
 
 
Melissa A. Waterhouse
 
 
 
Chief Executive Officer/ Principal Financial Officer
 
 
 
American Bio Medica (QB) (USOTC:ABMC)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more American Bio Medica (QB) Charts.
American Bio Medica (QB) (USOTC:ABMC)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more American Bio Medica (QB) Charts.